Existing standard-of-care targeted therapies (i.e., BRAF inhibitors) for CM are not available to the majority of advanced ALM patients due to a lower frequency of BRAFV600E/K mutations (20% versus 50% in other forms of CM [2]). The gene discussed is BRAF; the disease is cutaneous mastocytosis.